

7th international congress
of myology

MYOLOGY 2022

Sept. [12-15]

NICE Acropolis - FRANCE

MYOLOGY Presidents:

Shahragim Tajbakhsh


Elizabeth McNally

myology2022.org

© GENETHON - J.Cosette

PROGRAMME

AFM TÉLÉTHON
CURE THROUGH INNOVATION



7th international congress
of myology

MYOLOGY

Sept•[12•15]

2022

Sponsors

■ Gold sponsors



Inspired by patients.
Driven by science.

■ Silver sponsors



■ Others



The AFM-Telethon would like to thank CG Traduction & Interprétation (Groupe Tradutec), specialists in interpreting (in-person or remote/technical solutions and team of specialist interpreters), for its support in the form of a skills-based sponsorship programme.

Site : <https://www.societetraduction.fr>

Coordination AFM-Téléthon

Direction de la communication

Anne-Sophie Gonon
Emmanuelle Guiraud
Laurence Lespinard
Sabine Maillet-Crozet

Presidents

Shahragim Tajbakhsh

Director of the Stem cells and Development unit at Institut Pasteur in Paris (France)

Elizabeth McNally

Director of the Center for Genetic Medicine at Northwestern University's Feinberg School of Medicine in Chicago (USA)

Scientific organization committee

Coordinator

J. Andoni Urtizberea (Paris, France)

Members

Shahram Attarian (Marseille, France)
Odile Boespflug-Tanguy (Paris, France)
Serge Braun (Evry, France)
Gillian Butler-Browne (Paris, France)
Fabrice Chrétien (Paris, France)
Claude Desnuelle (Nice, France)
Bertrand Fontaine (Paris, France)
Eric Gilson (Nice, France)
Sabrina Sacconi (Nice, France)
Giorgio Tasca (Rome, Italy)

MYOLOGY 2022



Laurence Tiennot-Herment
President of AFM-Téléthon

In 2019, at our last Myology meeting in Bordeaux, we observed the first instances of innovative therapies for neuromuscular diseases, in particular the first gene therapy. Since then, despite the pandemic that shook the world, research has continued to accelerate, and three years after our last meeting we see increasing numbers of trials and results. More than ever, myology is at the cutting edge of therapeutic innovation, at the forefront of a medical revolution to serve as many patients as possible!

For patients and their families receiving these first therapies, the diagnosis now comes with a treatment proposal, which changes everything! What a joy to see these babies - previously condemned by the disease to short lives - regain strength and life. Also, what a great satisfaction to see the disease reversed or significantly slowed in older patients. However, a great many families are still awaiting treatment, and although for them this progress is a source of incredible hope, their legitimate expectations must not be dashed. And for our Association, which has been driving this innovation and providing massive support for research into muscle and related diseases for so many years, these are reasons not to give up but to continue the fight!

And we know that although we have witnessed the first victories, there are many tough challenges ahead. We need to continue research in order to understand the complex diseases that we still have not beaten, to improve current therapeutic tools, to identify new strategies and to solve issues concerning immune response and bioproduction on a large scale... In short, the revolution is only just beginning and we are relying on you to help us move it further forward.

On behalf of the AFM-Telethon patients and families, I'd like to thank you for being here in Nice, and I hope that the meeting is a successful one for you all, bringing new discoveries and breakthroughs for the treatment of neuromuscular diseases.



Shahragim Tajbakhsh
President of Myology 2022

Welcome one and all. As co-president of the scientific council of the AFM-Téléthon it is with great pleasure that I welcome you to the Nice Acropolis Congress Center from September 12-15th for 7th International Congress - Myology 2022, which is followed by “mitoNice”, the first international edition dedicated to mitochondrial medicine from September 15-17th.

Nice is a magical place, located on the French Riviera, with plenty of cultural attractions as well as a very active University with centuries old traditions that include a College of Medicine.

Much has transpired since our last conference in Bordeaux, including clinical trials using innovative therapies to combat neuromuscular diseases that have been considered to be untreatable. While emerging from a difficult pandemic, our perspectives have changed to some extent as we consider, with a new angle, the impact of outbreak diseases on patients with predisposed conditions. Our rich programme aims to capture the spirit of research activities in neuromuscular biology, spanning topics from basic research to clinical trials.

We continue to bridge the gap between fundamental studies on mechanisms that regulate muscle development, regeneration, and ageing to inform on how therapeutic strategies can be refined. On the other hand, clinical observations continue to bring novel insights into how disease models can be leveraged to understand the underlying etiology of debilitating myopathies. I hope that you will benefit fully from this opportunity to exchange and share knowledge across these domains while we advance our understanding of disease states at Myology 2022. Looking forward to seeing you there!



Elizabeth McNally
President of Myology 2022

I am delighted to welcome you to Nice and the 7th International Myology Congress. This meeting is being held in conjunction with the complementary mitoNice Congress. In these gatherings, you will learn from an international roster of speakers to bring you up to date information on “all things muscle” related to health and disease. The programme brings together many topics of interest to the muscle research and clinical communities. Despite pandemic and the challenges to conducting clinical, translational and basic research, there has been significant progress in understanding new mechanisms of muscle disease and developing new treatments for patients with neuromuscular disorders.

Many muscle diseases are driven by genetic alterations, including both primary mutations and genetic modifiers. The blend of these genetically driven targets is now combined with the new and emerging tools for editing, modifying or even replacing genes. There are many new models, which include human cells and animal models, and these models provide robust platforms for defining mechanisms and testing new approaches to therapy. Over the last more than two years, we have had limited opportunities to gather and exchange data and new ideas. Coming to the Myology and mitoNice congress will offer a wonderful venue, great colleagues, and enlightening exchange of ideas to promote novel and exciting science designed to help those with neuromuscular diseases.

Welcome one and all!

AFM-TÉLÉTHON

Cure through innovation



7th international congress of myology

Since it was created in 1958, the AFM-Téléthon has been fighting continuously against the disease driven by one objective: to cure neuromuscular diseases. From fundamental research to development of innovative therapies, our association conducts a strategy of innovation which benefits rare diseases at large.

Today, clinical trials are multiplying across the world and with the arrival of the first innovative therapy drugs, a new medicine is emerging. The impossible comes possible! The AFM-Téléthon is more determined than ever to tackle this new era and its challenges, by continuing to favour daring and innovation, therapeutic efficacy and access to the drug for all patients.

To accelerate the development of innovative therapies, the AFM-Téléthon has acquired a unique strike force:

> 3 laboratories at the forefront of innovative therapies, combined within the Biotherapies Institute for Rare Diseases:

- the **Institute of Myology** dedicated to muscles and their diseases, in particular with I-Motion, its children's and adults' clinical trials platform
- **Genethon** dedicated to gene therapy for rare diseases
- **I-Stem**, dedicated to research on stem cells and their therapeutic applications

> founding member of the **Foundation for Rare Diseases and Imagine Institute** in Paris

> **200 research and medical projects and young researchers** supported each year through its annual call for proposals

> support to **41 current and upcoming clinical trials** for diseases of muscles, vision, brain, heart, skin, liver, blood, etc.

> an '**innovative biotherapies and rare diseases**' seed fund created with Bpifrance: 7 start-up companies financed

As part of its strategy for 'Cure', AFM-Téléthon relies on its Scientific Council, chaired by Prof Odile Boespflug-Tanguy, geneticist and pediatrician, Inserm research director and Head of the Neuropaediatrics department (Robert Debré Hospital, Paris), comprising 85 international scientists, doctors and experts and a global network of 6,000 experts.

Beyond its annual call for projects, the AFM-Téléthon offers its support to numerous accredited strategic projects. From proof of concept to implementing clinical protocols, specialists in basic and preclinical research, experts in clinical development and regulatory affairs can support you throughout such projects.

➔ If you have a project, the AFM-Téléthon can support you.

Contact: spcsafm@afm-telethon.fr

afm-telethon.com

Programme at a glance

	Morning	Noon	Afternoon	Evening
Monday 12 September			<p>15:30-17:00: Pre-congress symposium</p> <p>17:30- 19:00:</p> <ul style="list-style-type: none"> • Opening ceremony • Opening lecture 	<p>19:00  Meet and greet time</p>
Tuesday 13 September	<p>8:30-10:00: Plenary session</p> <p>10:30-12:00: Parallel symposia</p>	<p>12:00-14:00: <i>Lunchbreak and exhibition</i></p> <p>12:00-13:00: Industry symposium: Argenx</p>	<p>14:00-15:00: Young investigator symposium</p> <p>15:00-16:00: Plenary session</p> <p>16:30-18:00: Parallel symposia</p>	
Wednesday 14 September	<p>8:30-10:00: Plenary session</p> <p>10:30-12:00: Parallel symposia</p>	<p>12:00-13:00: Industry symposium: Roche</p> <p>13:00-14:30:  <i>Poster lunch break organized by AFM-Telethon in the Poster room</i></p>	<p>14:30-16:00: Plenary session</p> <p>16:30-18:00: Parallel symposia</p>	<p>20:00  Networking dinner</p>
Thursday 15 September	<p>8:30-10:00: Plenary session</p> <p>10:30-12:00: Parallel symposia</p>	<p>12:00-13:00: Industry symposium: UCB</p> <p>13:00-14:00: <i>Lunchbreak and exhibition</i></p>	<p>14:00-15:00: Late breaking news</p> <p>15:00-17:00: Plenary session</p> <p>17:30-18:00: Handover ceremony: From Myology 2022 to mitoNice</p>	

PROGRAMME

Monday, September 12th

15:30-17:00 >>> Pre-congress symposium >>> Uniting myology forces in Europe?

GALLIENI 1-2

(Subject to availability of places)

Moderators : Alexandre MEJAT (Evry, France), Sabrina SACCONI (Nice, France)

- The Italian Association of Myology-networking Italy toward connecting Europe > *Gabriele SICILIANO (Pisa, Italy)*
- The British Myology Society > *Rosaline QUINLIVAN (London, UK)*
- Euro-NMD: European Reference Network > *Carla D'ANGELO (Paris, France)*
- The European Neuromuscular Centre > *Alexandra BREUKEL (Leiden, The Netherlands)*
- FILNEMUS: The french neuromuscular network > *Shahram ATTARIAN (Marseille, France)*

17:30- 18:00 >>> Opening ceremony

APOLLON AUDITORIUM

AFM-Téléthon President: Laurence TIENNOT-HERMENT

Myology Presidents: Elizabeth MCNALLY (Chicago, USA) & Shahragim TAJBAKHS (Paris, France)

18:00-18:45 >>> Opening lecture

APOLLON AUDITORIUM

- Story(ies) of astronomy on the French Riviera

Eric Lagadec, Astrophysicist at the Côte d'Azur Observatory and President of the French Society of Astronomy and Astrophysics



19:00 >>> Meet and greet time at the conference center

(RHODES ROOM)

Tuesday, September 13th

8:30-10:00 >>> Plenary lecture >>> **Development, regeneration and ageing (part 1)**

APOLLON AUDITORIUM

Moderators: Gillian BUTLER-BROWNE (Paris, France), Lee SWEENEY (Gainesville, USA)

8:30 • Molecular and functional diversity among satellite cell populations provides insights into disease

> *Shahragim TAJBAKHSH (Paris, France)*

9:00 • Notch signaling: an emerging therapeutic target for muscle wasting diseases

> *Yusuke ONO (Tokyo, Japan)*

9:30 • Myofiber syncytium - many identities in one cell

> *Minchul KIM (Illkirch-Graffenstaden, France)*

9:45 • Dissecting the regulatory program controlling trapezius muscle development at the head trunk interface

> *Camille DUMAS (Marseille, France)*



10:00-10:30 # **Coffee break and Visit of the exhibit hall and poster room**

(RHODES ROOM)

10:30-12:00 >>> Parallel session 1

ATHENA AUDITORIUM

• **Lessons from the pandemic**

Moderator: Guilhem SOLE (Bordeaux, France)

10:30 • COVID-19 and Myositis-a relevant problem?

> *Werner STENZEL (Berlin, Germany)*

11:00 • Telemedicine to overcome barriers in NMD-myths and realities

> *Gabriele SICILIANO (Pisa, Italy)*

11:30 • Evaluation of anti-SARs-CoV-2 vaccination efficacy in patients with severe neuromuscular diseases

> *Alexia DAMOUR (Bordeaux, France)*

11:45 • Safety of COVID-19 vaccination in a large French cohort of neuromuscular patients: data from the VACNEMUS study

> *Marlène BARNAY (Bordeaux, France)*

10:30-12:00 >>> Parallel session 2

APOLLON AUDITORIUM

• **Development, regeneration and ageing (part 2)**

Moderator: Fabrice CHRETIEN (Paris, France)

10:30 • Engineering human stem cells for advanced neuromuscular disease and therapy modelling

> *Saverio TEDESCO (London, UK)*

11:00 • LSD1-mediated demethylation of beta-catenin regulates muscle stem cell self-renewal potential

> *Isabella SCIONTI (Lyon, France)*

11:15 • Defective dystrophic thymus determines degenerative changes in skeletal muscle

> *Yvan TORRENTE (Milano, Italy)*

11:30 • USP18 a novel regulator of muscle cell differentiation and maturation, potentially regulating regeneration in dermatomyositis

> *Vered RAZ (Leiden, The Netherlands)*

11:45 • Satellite cell dynamics in growth and regeneration of skeletal muscle in normal and dystrophic mice

> *Terence PARTRIDGE (London, UK)*

12:00 -13:00 >>> • **Industry symposium - Argenx**

HERMÈS AUDITORIUM

“The gMG treatment individualization evolution: Implications for your patients”

12:00-14:00

Lunch break and Visit of the exhibit hall and poster room

(RHODES ROOM)

14:00-15:00 >>> Symposium >>> Young investigator symposium APOLLON AUDITORIUM

Moderators: Pascale BOMONT (Lyon, France), Thierry TOURSEL (Evry, France)

- 14:00 • Delivery and expression of large dystrophins using adeno-associated viral vector and protein trans-splicing mediated by split inteins
> **Hichem TASFAOUT (Seattle, USA)**
- 14:15 • Novel AAV capsid variant for muscle-directed gene therapy
> **Juliette LEMOINE (Evry, France)**
- 14:30 • Inactivating the lipid kinase activity of PI3K-C2 β is sufficient to rescue X-linked myotubular myopathy in mice
> **Marie GORET (Illkirch, France)**
- 14:45 • PARP3 promotes myogenic differentiation and skeletal muscle function in cooperation with the histone methyltransferase EZH2
> **Zuleyha YILDIRIM (Illkirch, France)**

15:00-16:00 >>> Plenary lecture >>> Advances and challenges in gene therapies (part 1) APOLLON AUDITORIUM

Moderator: Serge BRAUN (Evry, France)

- 15:00 • The management of safety of gene therapy of neuromuscular diseases, an emblematic example
> **Serge BRAUN (Evry, France)**
- 15:20 • Challenges of AAV Gene Therapy Development for Duchenne Muscular Dystrophy
> **Francesco MUNTONI (London, UK)**
- 15:40 • The liver as a model tissue to develop innovative solutions to the existing limitations of AAV gene therapy
> **Giuseppe RONZITTI (Evry, France)**



16:00-16:30 # Coffee break and Visit of the exhibit hall and poster room (RHODES ROOM)

16:30-18:00 >>> Parallel session 1 APOLLON AUDITORIUM

• **Motor neuron diseases**

Moderator: Claude DESNUELLE (Nice, France)

- 16:30 • The role of DNA epigenetics in modulating Spinal Muscular Atrophy
> **Piera SMERIGLIO (Paris, France)**
- 17:00 • Combination of BIO101 with antisense oligonucleotide therapy demonstrates synergistic beneficial effects in severe SMA-like mice
> **Cynthia BEZIER (Paris, France)**
- 17:20 • Spinal cord MRI for early detection of presymptomatic pathology in C9orf72-mutation carriers: a longitudinal neuroimaging study
> **Giorgia QUERIN (Paris, France)**
- 17:40 • Extracellular vesicle sphingomyelins as diagnostic biomarkers in motor neurone diseases
> **Stephanie DUGUEZ (Londonderry, UK)**

16:30-18:00 >>> Parallel session 2 ATHENA AUDITORIUM

• **Development, regeneration and ageing (part 3)**

Moderators: Eric GILSON (Nice, France), Shahragim TAJBAKHS (Paris, France)

- 16:30 • Dissecting stem cell regulation in skeletal muscle regeneration and aging through single - cell transcriptomics
> **Benjamin COSGROVE (Ithaca, USA)**
- 17:00 • Preliminary results of a multiparametric quantitative NMR ageing study at rest and during exercise in the lower leg in healthy subjects between 20 and 65 years of age
> **Alfredo LOPEZ KOLKOVSKY (Paris, France)**
- 17:15 • The histone variant H2A.Z prevents accumulation of DNA damage and acts as a gatekeeper for skeletal muscle aging
> **Laurent SCHAEFFER (Lyon, France)**
- 17:30 • The spectrum of IL-6 actions in healthy and bad aging and in muscle diseases
> **Antonio MUSARÒ (Roma, Italy)**
- 17:45 • Therapeutic approach based on GDF5 to counteract age-related muscle wasting
> **Massiré TRAORE (Paris, France)**

Wednesday, September 14th

8:30-10:00 >>> Plenary lecture >>> Cardiomyology APOLLON AUDITORIUM

Moderators: Karim WAHBI (Paris, France), Helge AMTHOR (Montigny-le-Bretonneux, France)

8:30 • A history of cardiomyology

> **Denis DUBOC** (Paris, France)

9:00 • Establishing new models for dystrophic cardiomyopathy

> **Elizabeth MCNALLY** (Chicago, USA)

9:30 • EV for cardiac repair: rationale and translational roadblocks

> **Philippe MENASCHE** (Paris, France)



10:00-10:30 # Coffee break and Visit of the exhibit hall and poster room (RHODES ROOM)

10:30-12:00 >>> Parallel session 1 APOLLON AUDITORIUM

• Myotonic syndromes

Moderator: Bertrand FONTAINE (Paris, France)

10:30 • Decoy gene therapy for Myotonic Dystrophy

> **Denis FURLING** (Paris, France)

11:00 • Clinical Trial readiness in DM1 and DM2

> **Frederica MONTAGNESE** (Munich, Germany)

11:30 • Mutation-driven personalized therapy in non-dystrophic myotonia

> **Jean-François DESAPHY** (Bari, Italy)

10:30-12:00 >>> Parallel session 2 ATHENA AUDITORIUM

• Muscle fibrosis

Moderator: Bruno PEAULT (Los Angeles, USA)

10:30 • Metabolic reprogramming of skeletal muscle by resident macrophages points to CSF1R inhibitors as muscular dystrophy therapeutics

> **Farshad Babaeijandaghi** (Vancouver, Canada)

11:00 • Preclinical studies support a potential interest in growth hormone secretagogues in Duchenne muscular dystrophy by modulation of fibrosis

> **Annamaria DE LUCA** (Bari, Italy)

11:30 • Adipogenic properties of fibro-adipogenic precursor cells in normal, regenerating and DMD mouse skeletal muscle

> **Georgiana PANCI** (Lyon, France)

11:45 • Muscle fibrosis: a vicious circle between human fibroadipogenic progenitors and muscle fibers

> **Mona BENSALAH** (Paris, France)

12:00-13:00 >>> Industry symposium - Roche HERMÈS AUDITORIUM

Heading to the future of clinical research in neuromuscular disorders

13:00-14:30



Poster lunch break organized by AFM-Telethon in the poster room (RHODES ROOM)

14:30-16h00 >>> Plenary lecture >>> Advances and challenges in gene therapies (part 2) **APOLLON AUDITORIUM**

Moderator: Odile BOESPFLUG-TANGUY (Paris, France)

14:30 • X-linked myotubular myopathy and liver dysfunction

> **Ana BUJ-BELLO (Evry, France)**

15:00 • Modelling and editing Duchenne Muscular Dystrophy

> **Wolfram-Hubertus ZIMMERMANN (Goettingen, Germany)**

15:30 • Application of CRISPR/Cas9 strategy for gene therapy of Myotonic Dystrophy type 1

> **Germana FALCONE (Monterotondo, Italy)**



16:00-16:30 # Coffee break and Visit of the exhibit hall and poster room **(RHODES ROOM)**

16:30-18:00>>> Parallel session 1 **APOLLON AUDITORIUM**

• **Neuromuscular junction**

Moderator: Shahram ATTARIAN (Marseille, France)

16:30 • New treatments for autoimmune myasthenia gravis

> **Emilien DELMONT (Marseille, France)**

17:00 • Use of human pluripotent stem cells for neuromuscular disorders

> **Cécile MARTINAT (Evry, France)**

17:30 • Targeting the neuromuscular junction (NMJ) to treat congenital myasthenic syndromes and inherited motor neuropathies with NMJ dysfunction

> **Sally SPENDIFF (Ottawa, Canada)**

16:30 -18:00 >>> Parallel session 2 **ATHENA AUDITORIUM**

• **FSHD**

Moderator: Yegor VASSETZKY (Villejuif, France)

16:30 • Facioscapulohumeral muscular dystrophy: clinical, genetic and nuclear heterogeneity from a single locus

> **Sylvère VAN DER MAAREL (Leiden, The Netherlands)**

17:00 • Inflammatory responses in FSHD

> **Sabrina SACCONI (Nice, France)**

17:30 • Induced pluripotent stem cells for modeling neuromuscular disorders: the example of FacioScapuloHumeral Dystrophy

> **Frédérique MAGDINIER (Marseille, France)**



20:00 >>> Networking dinner (not included in registration fees-separate registration required)

20:00

Networking dinner

at the Nice Acropolis Center

(Muses room - Level 3)

Thursday, September 15th

8:30-10:00 >>> Plenary lecture >>> New concepts APOLLON AUDITORIUM

Moderator: Giorgio TASCA (Roma, Italy)

8:30 • Oculopharyngodistal myopathy

> *Ichizo Nishino (Tokyo, Japan)*

9:00 • Latest advances in CMT: Disease mechanisms and novel therapy concepts in demyelinating neuropathy

> *Michael Sereda (Göttingen, Germany)*

9:30 • The node of Ranvier: a vulnerable site for autoimmunity

> *Luis Querol (Barcelona, Spain)*



10:00-10:30 # Coffee break and Visit of the exhibit hall and poster room (RHODES ROOM)

10:30-12:00 >>> Parallel session 1 APOLLON AUDITORIUM

• New tools

Moderator: Ketan PATEL (Reading, UK)

10:30 • 3D printed, anisotropic, and porous dense collagen hydrogels to mimic skeletal muscle extracellular matrix

> *Marie CAMMAN (Paris, France)*

11:00 • The generation of a new preclinical rat model for DMD leads to the identification of the TSHR pathway as a regulator of senescence in muscle stem cells

> *Frédéric RELAIX (Créteil, France)*

11:30 • A novel extrusion 3D bio-printing system for skeletal muscle tissue engineering

> *Stefano TESTA (Marseille, France)*

10:30-12:00 >>> Parallel session 2 ATHENA AUDITORIUM

• LGMD

Moderator: Elizabeth MCNALLY (Chicago, USA)

10:30 • The first standards of care guidelines for a limb girdle muscular dystrophy

> *Volker STRAUB (Newcastle, UK)*

11:00 • Genetic profile of patients with limb girdle muscular weakness in the Chilean population

> *Jorge BEVILACQUA (Santiago, Chile)*

11:30 • Preclinical development of a gene therapy for three prevalent forms of LGMD

> *Isabelle RICHARD (Evry, France)*

12:00-13:00 >>> Industry symposium - UCB HERMÈS AUDITORIUM

Auto-immune myasthenia: epidemiological description of the French myasthenic population and its therapeutic management; patients' expectations concerning new therapies in MG

13:00-14:00

Lunch break and Visit of the exhibit hall and poster room (RHODES ROOM)

14:00-15:00 >>> Late breaking news APOLLON AUDITORIUM

Moderators: Jean-Thomas VILQUIN (Paris, France)

14:00 • Update on the development of Givinostat in DMD

> **Paolo Umberto BETTICA** (Cinisello Balsamo, Italy)

14:15 • An AAV-ShRNA DUX4-based therapy to treat FacioScapuloHumeral muscular Dystrophy (FSHD)

> **Julie DUMONCEAUX** (London, UK)

14:30 • CD38-NADase is a major contributor to DMD phenotype

> **Sabine DE LA PORTE** (Montigny-le-Bretonneux, France)

14:45 • Severe mitochondrial dysfunctions caused by a heterozygous DES mutation in iPSC-derived cardiomyocytes

> **Yeranuhi HOVHANNISYAN** (Angers, France)

15:00-17:00 >>> Plenary lecture >>> Mitochondria & muscle APOLLON AUDITORIUM

Moderators: Olivier BARIS (Angers, France), Holger PROKISCH (Munich, Germany), Rita HORVATH (Cambridge, UK)

15:00 • Mechanisms of mitochondrial myopathy: mosaic stress responses, metabolic remodeling and curable NAD-deficiency

> **Anu SUOMALAINEN** (Helsinki, Finland)

15:45 • Regulation of skeletal muscle bioenergetics through mitochondrial calcium during exercise and aging

> **Jerôme FEIGE** (Lausanne, Switzerland)

16:15 • Structural heterogeneity of the human respiratory chain

> **Cristina UGALDE** (Madrid, Spain)

16:30 • OMA1 mediates local and global stress responses against protein misfolding in CHCHD10 mitochondrial myopathy

> **Derek NARENDRA** (Bethesda, USA)

16:45 • Efficacy and genetic safety of deoxyribonucleosides as a therapy for mitochondrial DNA replication defects caused by mutations in genes involved in mtDNA maintenance

> **Ramon MARTÍ** (Barcelona, Spain)



17:00-17:30 # Coffee break and Visit of the exhibit hall and poster room AGORA 2

17:30-18:00 >>> Plenary lecture >>> Handover ceremony: From Myology 2022 to mitoNice APOLLON AUDITORIUM

POSTERS

FUNDAMENTAL MYOLOGY

P01 / Animal Models

From N°1 to N°40

P02/ Fibrosis

From N°41 to N°52

P03/ Miscellaneous

From N°53 to N°86

P04/ Muscle Function

From N°87 to N°138

P05/ Muscle Regeneration

From N°139 to N°167

P06/ Myogenesis

From N°168 to N°190

CLINICAL MYOLOGY

P07/ Cardiomyology

From N°191 to N°195

P08/ Cell therapies

From N°196 to N°198

P09/ Congenital muscular dystrophies

From N°199 to N°201

P10/ Congenital myopathies

From N°202 to N°209

P11/ Covid-19

N°210

P12/ Diagnostic tools

From N°211 to N°217

P13/ Distal myopathies

From N°218 to N°222

P14/ Duchenne muscular dystrophy

From N°223 to N°247

P15/ Facioscapulohumeral dystrophy (FSHD)

From N°248 to N°252

P16/ Gene therapies

From N°253 to N°264

P17/ Hereditary neuropathies

From N°265 to N°268

P18/ Immune-mediated myopathies and neuropathies

From N°269 to N°276

P19/ Limb girdle muscular dystrophies

From N°277 to N°291

P20/ Metabolic myopathies

From N°292 to N°293

P21/ Miscellaneous

From N°294 to N°296

P22/ Motor neuron diseases (including SMA)

From N°297 to N°307

P23/ Myasthenia gravis & congenital myasthenic syndromes

From N°308 to N°320

P24/ Myotonic syndromes

From N°321 to N°329

P25/ Outcome measures


From N°330 to N°336

P26/ Pharmacological therapies


From N°337 to N°340

P27/ Young Investigator Poster


From N°341 to N°380



BOOTHS



- 4 VECTOR BUILDER
- 5 PFIZER
- 6 ALEXION
- 7 SAREPTA
- 8 PTC THERAPEUTICS
- 9 GENETHON
- 10 INSTITUT DE MYOLOGIE
- 11 AFM-TELETHON
- 12 ENMC
- 14 UCB
- 15 ARGENX
- 16 ROCHE
- 17 LUPIN
- 18 EURO-NMD



Discover Nice, Capital of the French Riviera



On the Mediterranean coast, only a few kilometres from Italy, Nice has all the charm of a southern city. Even before you land on the Nice tarmac, you will be breathless by the view that awaits you through the window. No wonder Nice Côte d'Azur International Airport has been on the podium of the most beautiful approaches in the world for several years in a row! In addition to the extraordinary monochrome of the Mediterranean Sea, the panorama of the mountains (snow-covered in winter) is also awe-inspiring.

Capital of the French Riviera, Nice is the perfect embodiment of the art of living. The blue of the Mediterranean, the marvellous light that can only be found here, breakfast on a sunny terrace, a quiet stroll through the narrow streets of the old town, lunch on a hotel terrace, an afternoon of shopping in the city's prestigious boutiques, a dip in the sea, an aperitif on the Cours Saleya, a classical music concert at the Opera, a gala evening at the Casino, a candlelit dinner in a Michelin-starred restaurant...Nice is all of these things and more!

Old Nice is, in itself, a festival of sensations! Narrow streets, yellow and ochre facades, craftsmen's shops and small boutiques, restaurants and lively squares make up the soul of this old quarter, which is alive day and night, not forgetting, of course, the Cours Saleya market, classified as one of the exceptional markets in France! From the top of the listed site of the Colline du Château, you can enjoy a remarkable view of the Baie des Anges, the old town and the port, from sunrise to sunset.

©Tourism office of Nice / More information: www.explorenicetotedazur.com



Nice Acropolis Convention Centre

1 esplanade John Fitzgerald Kennedy
06000 Nice

		
<ul style="list-style-type: none">• From the airport: Bus n° 98 - Stop: Cathédrale Vieille-Ville, and the tramway direction Pasteur - Stop: Acropolis.	<ul style="list-style-type: none">• From the SNCF Station: The tramway at the stop Thiers direction Pasteur - Stop: Acropolis.	<ul style="list-style-type: none">• Palais des Congrès: 43°42'21.4"N 7°16'52.1"E <p>Parkings near the Nice Acropolis:</p> <ul style="list-style-type: none">- Parking Acropolis- <i>[Parking Jean Bouin]</i>- Parking Promenade des Arts <i>[Parking Promenade des Arts]</i>



Association recognized as a public utility

1, rue de l'Internationale - BP 59
91002 Évry-Courcouronnes cedex - France
Phone: 33 (0)1 69 47 28 28 - Fax: 33 (0)1 60 77 12 16
Headquarters: AFM - Institut de Myologie
47-83, boulevard de l'Hôpital -
75651 Paris cedex 13 - France
www.afm-telethon.fr